Study #2023-0103
A controlled Multi-Arm phase 1 umbrella study evaluating the safety and feasibility of T-Cell Receptor Engineered Donor T-Cells Targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 positive patients undergoing Haploidentical allogeneic peripheral blood stem cell transplantation
MD Anderson Study Status
Enrolling
Treatment Agent
SOC + TSC-100, SOC + TSC-101
Description
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
AML, Myelodysplastic Syndromes, ALL, Adult
Study phase:
Phase I
Physician name:
Uday Popat
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.